CH3 Domain Charge Redistribution for Bispecific Antibody Assembly
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current bispecific antibody technologies face challenges in achieving optimal yields and product quality due to the formation of homodimers during the expression of non-identical heavy chains, which affects safety, efficacy, and productivity, and existing charge pair technologies like electrostatic steering may yield suboptimal results.
Innovation Solution
The development of a heteromultimer with specific amino acid substitutions in the CH3 domains, such as D399K and K439D/E in one domain and K409D/E, K392D/E, and E356K in the other, to enhance heterodimerization and reduce homodimer formation, improving the ratio of correct chain pairing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If electrostatic steering with charge pair mutations is used to drive heterodimerization, then heterodimer formation is promoted, but homodimer formation cannot be completely prevented and yields remain suboptimal
Solution Approach 1:
The patent applies local quality by creating asymmetric charge distributions at specific localized positions within the CH3 domain interface. Instead of uniform charge modification, the invention places specific charged residues (e.g., Lysine at position 409, Aspartic acid at position 392) at critical heterodimerization interface locations, creating localized electrostatic attraction zones that selectively promote heterodimer formation while minimizing homodimer formation.
Solution Approach 2:
The patent implements asymmetry by introducing non-reciprocal charge pair mutations between the two heavy chains. One chain carries specific charge modifications (e.g., K409D, K392D) while the other chain has different modifications (e.g., D399K, K439D), creating an asymmetric electrostatic steering field that directs specific heterodimer assembly while preventing symmetric homodimer formation.
2Reliability
If charge pair mutations are introduced to enable electrostatic steering, then heterodimerization is enhanced, but the complexity of the protein structure increases
Solution Approach 1:
The patent applies parameter changes by modifying the electrostatic parameters of the CH3 domain interface through targeted amino acid substitutions. The invention changes the charge distribution parameters (introducing positive Lysine or negative Aspartic acid residues) at specific spatial coordinates within the protein structure, thereby altering the electrostatic potential landscape to favor heterodimerization without fundamentally changing the overall protein fold or architecture.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in a higher yield of multispecific antigen binding proteins with reduced impurities and improved product quality, as measured by SEC and Protein A purification, enhancing the therapeutic potential of bispecific antibodies.
Implementation Method 1
The electrostatic steering phenomenon, enabled by the incorporation of charge pair mutations (CPMs), is one of the preferred technologies with many bispecifics currently in clinical development. By introducing negative charges on one chain and positive charges on the other, attractive electrostatic forces drive heterodimerization while repulsive forces prevent homodimer formation.
Data Source
AI summary
The clinical potential of multispecific antibodies like bispecific and trispecific antibodies shows great promise for targeting complex diseases. However, the generation of those molecules presents great challenges particularly in regard to achieving acceptable expression levels free from mis-paired polypeptides. The presently claimed invention is directed to multispecific antigen binding proteins which improve upon existing charge pair technologies by redistributing the engineered charges within the CH3 regions of a heteromultimer.